Breaking Finance News

Baader Wertpapierhandelsbank announced Bayer (ETR:BAYN), stepping up its target to 81.00EUR today

Just yesterday Bayer (ETR:BAYN) traded 0.00% even at 88.31EUR. BAYN’s 50-day average is 0.04EUR and its two hundred day average is 0.03EUR. With the last stock price close up -4.07% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. 0 shares of the stock were exchanged, down from an avg. volume of 215

Baader Wertpapierhandelsbank upped the price target of Bayer (ETR:BAYN) to 81.00EUR reporting a possible downside of -0.08%.

On 9/29/2016, Baader Wertpapierhandelsbank released a statement about Bayer (ETR:BAYN) raised the target price from 0.00EUR to 81.00EUR that suggested a downside of -0.08%.

See Chart Below

Bayer (ETR:BAYN)

With a total market value of 0 EUR, Bayer has with a 52 week low of 0.03EUR and a 52 week high of 0.04EUR .

About Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *